Background: The Hamilton Depression Rating Scale (HAM-D) and the Montgomery Asberg Depression Rating Scale (MADRS) are scales used frequently to rate the symptoms of depression. There are many situations in which it is important to know what a given total score or a percent reduction from baseline score of one scale means in relation to the other scale.
Method: We used the equipercentile linking method to identify corresponding scores of simultaneous HAM-D and MADRS ratings in 4388 patients from 31 mirtazapine trials in major depressive disorder. Data were collected at baseline and at weeks 1, 2 and 4.
Results: HAM-D scores of 10, 20, 30 and 40 roughly corresponded to MADRS scores of 13, 26, 39 and 52-53, respectively. An absolute HAM-D improvement of 10, 20, 25 points corresponded to a MADRS improvement of 12, 26, and 34. A percentage improvement from baseline of the HAM-D was approximately the same as a percentage improvement on the MADRS.
Conclusion: These results are important for the comparison of trials that used the HAM-D and MADRS. We present conversion tables for future research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2017.09.042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background And Objective: Inadequate response to antidepressant monotherapy is common among patients with major depressive disorder (MDD). The efficacy and safety of adjunctive brexpiprazole 2 mg/day has recently been confirmed during the 6-week, randomized, placebo-controlled phase 2/3 (BLESS) study, which evaluated brexpiprazole at 1 mg/day and 2 mg/day versus placebo as adjunctive therapy to antidepressant therapies in 740 Japanese patients with MDD and an inadequate response to antidepressant monotherapy. This study evaluated the long-term safety and efficacy of adjunctive fixed-dose brexpiprazole 2 mg/day in Japanese patients with MDD.
View Article and Find Full Text PDFEvaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis.
Front Psychiatry
July 2024
Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States.
Article Synopsis
- Zuranolone is being studied for its effectiveness in treating major depressive disorder (MDD) and postpartum depression (PPD), particularly in patients with or without insomnia.
- A meta-analysis of eight randomized controlled trials (RCTs) involving 2031 patients showed significant improvements in depressive symptoms, particularly by day 15, as measured by various depression and anxiety rating scales.
- The findings support zuranolone as a promising treatment option for MDD and PPD, although some measures showed less significant changes and serious adverse events were minimal across all groups.
Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis.
Front Neurosci
April 2024
Department of Data Analytics, BPP University, London, United Kingdom.
Article Synopsis
- Zuranolone (SAGE-217) is a newly FDA-approved antidepressant for postpartum depression (PPD) and is currently being tested for its effectiveness in treating Major Depressive Disorder (MDD) and essential tremors (ET).
- A review of four clinical trials with 1,357 patients showed that Zuranolone significantly improved depression ratings (HAM-D, MADRS, HAM-A) compared to a placebo on the 15th day of treatment.
- While Zuranolone was associated with a higher response and remission rate, it also had a significant occurrence of treatment-emergent adverse events (TEAEs), indicating some safety concerns compared to placebo.
Therapeutic Potential of Buprenorphine in Depression: A Meta-Analysis of Current Evidence.
J Clin Med Res
March 2024
Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Background: Emerging research indicates buprenorphine, used in management of opioid use disorder, has attracted interest for its potential in treating a variety of psychiatric conditions. This meta-analysis aimed to determine the efficacy of buprenorphine in treating symptoms of depression.
Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, a search was conducted of several databases until April 25, 2022, for English language articles related to buprenorphine and its use in treating various mental health conditions.
Role of adjunctive cariprazine for treatment-resistant depression in patients with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.
Asian J Psychiatr
May 2024
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan. Electronic address:
Introduction: Cariprazine is an orally active dopamine D3-preferring D3/D2 receptor and serotonin 5-HT1A receptor partial agonist, being considered as a treatment for refractory MDD. Therefore, we aim to perform the first meta-analysis of current literature, to collate changes in depression from baseline and assess tolerability of adjunctive cariprazine in MDD populace.
Methods: PubMed, Embase, Google Scholar, ClinicalTrials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!